BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26550991)

  • 1. DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes.
    Zhang M; Zhang S; Wen Y; Wang Y; Wei Y; Liu H; Zhang D; Su J; Wang F; Zhang Y
    PLoS One; 2015; 10(11):e0142279. PubMed ID: 26550991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
    Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
    Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors.
    Klajic J; Fleischer T; Dejeux E; Edvardsen H; Warnberg F; Bukholm I; Lønning PE; Solvang H; Børresen-Dale AL; Tost J; Kristensen VN
    BMC Cancer; 2013 Oct; 13():456. PubMed ID: 24093668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.
    Xu J; Shetty PB; Feng W; Chenault C; Bast RC; Issa JP; Hilsenbeck SG; Yu Y
    BMC Cancer; 2012 Jun; 12():243. PubMed ID: 22695491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.
    Izadi P; Mehrdad N; Foruzandeh F; Reza NM
    Asian Pac J Cancer Prev; 2012; 13(8):4113-7. PubMed ID: 23098526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
    Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
    Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity-associated methylation in breast tumors: a possible link to disparate outcomes?
    Do WL; Conneely K; Gabram-Mendola S; Krishnamurti U; D'Angelo O; Miller-Kleinhenz J; Gogineni K; Torres M; McCullough LE
    Breast Cancer Res Treat; 2020 May; 181(1):135-144. PubMed ID: 32236829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.
    Hill VK; Ricketts C; Bieche I; Vacher S; Gentle D; Lewis C; Maher ER; Latif F
    Cancer Res; 2011 Apr; 71(8):2988-99. PubMed ID: 21363912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of DNA methylation marker of paired-like homeodomain transcription factor 2 and growth receptors in invasive ductal carcinoma of the breast.
    Wan Abdul Rahman WF; Fauzi MH; Jaafar H
    Asian Pac J Cancer Prev; 2014; 15(19):8441-5. PubMed ID: 25339043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
    Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH
    Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation and hormone receptor status in breast cancer.
    Benevolenskaya EV; Islam AB; Ahsan H; Kibriya MG; Jasmine F; Wolff B; Al-Alem U; Wiley E; Kajdacsy-Balla A; Macias V; Rauscher GH
    Clin Epigenetics; 2016; 8():17. PubMed ID: 26884818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.
    Conway K; Edmiston SN; Tse CK; Bryant C; Kuan PF; Hair BY; Parrish EA; May R; Swift-Scanlan T
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):921-30. PubMed ID: 25809865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.
    Wu J; Fang Y; Lin L; Fei X; Gao W; Zhu S; Zong Y; Chen X; Huang O; He J; Zhu L; Chen W; Li Y; Shen K
    Oncotarget; 2017 Jun; 8(24):38706-38716. PubMed ID: 28404972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
    Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
    Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.
    Fackler MJ; Umbricht CB; Williams D; Argani P; Cruz LA; Merino VF; Teo WW; Zhang Z; Huang P; Visvananthan K; Marks J; Ethier S; Gray JW; Wolff AC; Cope LM; Sukumar S
    Cancer Res; 2011 Oct; 71(19):6195-207. PubMed ID: 21825015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.